These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 397762)

  • 1. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
    Yu AL; Kung FH; Bakay B; Nyhan WL
    Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
    Wortmann RL; Holcenberg J; Poplack DG
    Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
    [No Abstract]   [Full Text] [Related]  

  • 5. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to deoxycoformycin in mature T cell malignancies.
    Ho AD; Stryckmans P; Zittoun R
    Br Med J (Clin Res Ed); 1987 Dec; 295(6611):1483-4. PubMed ID: 3500754
    [No Abstract]   [Full Text] [Related]  

  • 7. Decreased NAD+ content in human T lymphoblastoid cells treated simultaneously with 2'-deoxycoformycin and 2'-deoxyadenosine.
    Koya M; Kanoh T; Uchino H; Ueda K
    Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1003-11. PubMed ID: 3877388
    [No Abstract]   [Full Text] [Related]  

  • 8. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
    Kefford RF; Fox RM
    Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemic cells.
    Sylwestrowicz T; Piga A; Murphy P; Ganeshaguru K; Russell NH; Prentice HG; Hoffbrand AV
    Br J Haematol; 1982 Aug; 51(4):623-30. PubMed ID: 6980665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2' Deoxycoformycin and human hemopoietic cells in culture.
    Jurjus AR; Ridgeway A; Witz IP
    Dev Comp Immunol; 1984; 8(4):931-7. PubMed ID: 6240421
    [No Abstract]   [Full Text] [Related]  

  • 12. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated pentostatin (2'deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia.
    Dillman RO; Yu AL; Qiao CN
    West J Med; 1988 Mar; 148(3):334-7. PubMed ID: 3259051
    [No Abstract]   [Full Text] [Related]  

  • 14. Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin.
    Brito-Babapulle F; Huang D; Lavender P; Galton D; Catovsky D
    Eur J Haematol; 1988 Feb; 40(2):185-7. PubMed ID: 3257929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical consequences of 2'-deoxycoformycin treatment in a patient with T-cell lymphoma. Some unusual findings.
    de Korte D; Haverkort WA; van Leeuwen EF; Roos D; van Gennip AH
    Cancer; 1987 Aug; 60(4):750-5. PubMed ID: 3496148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
    O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
    Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin).
    Spiers AS; Davis MP; Levine M; Li CY; Mangan KF; Mazza JJ; Neu LT; O'Brien J; Rauch AE; Wiltsie JC
    Scand J Haematol; 1985 Jan; 34(1):57-67. PubMed ID: 2578689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
    Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
    Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor of 2', 5'-oligoadenylate synthetase induced in human T lymphoblastoid cell line treated with deoxyadenosine, deoxycoformycin and interferon.
    Heike T; Katamura K; Kubota M; Shinomiya K; Mikawa H
    Adv Exp Med Biol; 1986; 195 Pt B():683-7. PubMed ID: 3490130
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias.
    Ganeshaguru K; Ho AD; Piga A; Catovsky D; Hoffbrand AV
    Leuk Res; 1987; 11(10):941-5. PubMed ID: 3500370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.